161 related articles for article (PubMed ID: 24801755)
21. Current clinical and laboratory strategies to augment the efficacy of immunotherapy in multiple myeloma.
Gorschlüter M; Ziske C; Glasmacher A; Schmidt-Wolf IG
Clin Cancer Res; 2001 Aug; 7(8):2195-204. PubMed ID: 11489792
[TBL] [Abstract][Full Text] [Related]
22. Galectin-3 is induced in rheumatoid arthritis synovial fibroblasts after adhesion to cartilage oligomeric matrix protein.
Neidhart M; Zaucke F; von Knoch R; Jüngel A; Michel BA; Gay RE; Gay S
Ann Rheum Dis; 2005 Mar; 64(3):419-24. PubMed ID: 15345499
[TBL] [Abstract][Full Text] [Related]
23. Advances in the biology of multiple myeloma: therapeutic applications.
Anderson K
Semin Oncol; 1999 Oct; 26(5 Suppl 13):10-22. PubMed ID: 10528890
[TBL] [Abstract][Full Text] [Related]
24. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
[TBL] [Abstract][Full Text] [Related]
25. Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro.
O'Driscoll L; Linehan R; Liang YH; Joyce H; Oglesby I; Clynes M
Anticancer Res; 2002; 22(6A):3117-25. PubMed ID: 12530054
[TBL] [Abstract][Full Text] [Related]
26. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
[TBL] [Abstract][Full Text] [Related]
27. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer.
Wolf JK; Bodurka DC; Gano JB; Deavers M; Ramondetta L; Ramirez PT; Levenback C; Gershenson DM
Gynecol Oncol; 2004 Aug; 94(2):442-8. PubMed ID: 15297186
[TBL] [Abstract][Full Text] [Related]
28. Dendritic cell immunotherapy in ovarian cancer.
Stiff PJ; Czerlanis C; Drakes ML
Expert Rev Anticancer Ther; 2013 Jan; 13(1):43-53. PubMed ID: 23259426
[TBL] [Abstract][Full Text] [Related]
29. Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model.
Stannard KA; Collins PM; Ito K; Sullivan EM; Scott SA; Gabutero E; Darren Grice I; Low P; Nilsson UJ; Leffler H; Blanchard H; Ralph SJ
Cancer Lett; 2010 Dec; 299(2):95-110. PubMed ID: 20826047
[TBL] [Abstract][Full Text] [Related]
30. Extracellular functions of galectin-3.
Ochieng J; Furtak V; Lukyanov P
Glycoconj J; 2002; 19(7-9):527-35. PubMed ID: 14758076
[TBL] [Abstract][Full Text] [Related]
31. Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins.
Sioud M; Mobergslien A; Boudabous A; Fløisand Y
Int J Oncol; 2011 Feb; 38(2):385-90. PubMed ID: 21165555
[TBL] [Abstract][Full Text] [Related]
32. Cellular immunotherapy for multiple myeloma.
Rosenblatt J; Avigan D
Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
[TBL] [Abstract][Full Text] [Related]
33. Multiple myeloma and its therapies: to what extent do they contribute to the increased incidence of second malignant neoplasms?
Dasanu CA; Mewawalla P; Grabska J
Curr Med Res Opin; 2012 Jul; 28(7):1129-40. PubMed ID: 22533678
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy opportunities in ovarian cancer.
Chu CS; Kim SH; June CH; Coukos G
Expert Rev Anticancer Ther; 2008 Feb; 8(2):243-57. PubMed ID: 18279065
[TBL] [Abstract][Full Text] [Related]
35. Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.
Santin AD; Bellone S; Underwood LJ; O'Brien TJ; Ravaggi A; Pecorelli S; Cannon MJ
Minerva Ginecol; 2002 Apr; 54(2):133-44. PubMed ID: 12032451
[TBL] [Abstract][Full Text] [Related]
36. Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer.
John CM; Leffler H; Kahl-Knutsson B; Svensson I; Jarvis GA
Clin Cancer Res; 2003 Jun; 9(6):2374-83. PubMed ID: 12796408
[TBL] [Abstract][Full Text] [Related]
37. Biology and treatment of multiple myeloma.
Tosi P; Gamberi B; Giuliani N
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 1):81-6. PubMed ID: 16399590
[TBL] [Abstract][Full Text] [Related]
38. The Role of the Immune System in Ovarian Cancer and Implications on Therapy.
Menderes G; Schwab CL; Black J; Santin AD
Expert Rev Clin Immunol; 2016 Jun; 12(6):681-95. PubMed ID: 26821930
[TBL] [Abstract][Full Text] [Related]
39. Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment.
Schoutrop E; Moyano-Galceran L; Lheureux S; Mattsson J; Lehti K; Dahlstrand H; Magalhaes I
Semin Cancer Biol; 2022 Nov; 86(Pt 3):207-223. PubMed ID: 35395389
[TBL] [Abstract][Full Text] [Related]
40. Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression.
Wang L; Guo XL
Biomed Pharmacother; 2016 Mar; 78():165-171. PubMed ID: 26898438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
